Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
180 participants
INTERVENTIONAL
2026-01-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of TA-65MD on Healthy Volunteers
NCT02766790
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
NCT01753674
TA-65 Pharmacokinetic Study
NCT02731807
Effects of TA-65, a Telomerase Activator on Metabolic Syndrome
NCT02531334
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TA-65
TA-65 (250 U) taken once per day
TA-65
TA-65 is a purified small molecule extracted from Astragalus root
Placebo
Placebo taken once per day
Placebo
Inactive formulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TA-65
TA-65 is a purified small molecule extracted from Astragalus root
Placebo
Inactive formulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with clinical diagnosis of CAD
Exclusion Criteria
* Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr)
* Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
* Heart Failure
* Renal Impairment
* \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
* Type 1 or type 2 diabetes
* Uncontrolled hypertension
* Current tobacco use or within last 6 months
* BMI \> 35
* Hyperlipidemia
* Hypercholesterolemia
* Use of anti-coagulant drugs
* Use of anti-platelet drugs
* Erectile dysfunction medication in the past 6 months
* Use of topical/non-topical steroids in last 6 months
* Hormone replacement therapy (Post-Menopause or Gender Reassignment)
* History of retinopathy
* Documented neuromuscular disorders
* Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
* Pregnancy (young female subjects)
* Allergy to lidocaine
* Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
* Active COVID-19 or within the past 3 months
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Louisville
OTHER
Penn State University
OTHER
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William Hughes
Postdoc Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Beyer, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Associate Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TA-65 and Vascular Aging
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.